Analysis of randomized controlled studies comparing ablation with antiarrhythmic drugs

Area of Science:

• Cardiology
• Electrophysiology

Background:

• Catheter ablation is a key treatment for atrial fibrillation (AF).
• Previous studies suggest catheter ablation is more effective than antiarrhythmic drugs as first-line therapy for AF.
• Concerns exist regarding the adequacy of drug dosages and adherence in prior trials.

Purpose of the Study:

• To evaluate the dosages and adherence of antiarrhythmic drugs used in randomized trials comparing them to catheter ablation for first-line AF treatment.
• To identify factors that may influence the reported superiority of catheter ablation.

Main Methods:

• A systematic literature search of PubMed and Medline was conducted.
• Randomized trials comparing first-line antiarrhythmic drug therapy with catheter ablation for AF were identified and analyzed.
• Drug dosages and patient adherence were assessed in the included studies.

Main Results:

• A significant proportion of patients (20-43%) in the drug arm received suboptimal doses of flecainide, propafenone, and sotalol.
• Early discontinuation or non-receipt of prescribed antiarrhythmic drugs occurred in 2.5% to 10.4% of patients.
• Up to 10% of patients in the catheter ablation arm received adjunctive antiarrhythmic drug therapy.

Conclusions:

• The superiority of catheter ablation over antiarrhythmic drugs for first-line AF treatment may be overestimated due to suboptimal drug dosing and adherence in comparative trials.
• Further research is needed to confirm the optimal therapeutic strategies for AF management, considering adequate drug regimens and patient adherence.